STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1) is a six-pass transmembrane ferric oxidoreductase with highly restricted expression in prostate cancer and Ewing sarcoma, offering an exceptional therapeutic window for targeted therapies. Key mutations (e.g., rs4015375, rs2888782) are cataloged in dbSNP, and the protein's ferric oxidoreductase domain is critical for its biological function.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for STEAP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | STEAP1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). Theoretical MW confirmed. |
View STEAP1 Products |
| Gene Delivery | STEAP1 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction. Preserves native six-pass transmembrane conformation. |
View STEAP1 Products |
| Benchmark Ab | Anti-STEAP1 (Benchmark Sequences including Xaluritamig and AZD7495 biosimilars) Recombinant positive control for assay development. HEK293 expressed, Sequence Verified. |
View STEAP1 Products |
| Validator | STEAP1 siRNA Set For knockdown verification and specificity controls. |
View STEAP1 Products |
| Related Target A | STEAP2 Paralog metalloreductase; essential for subfamily selectivity counter-screening. |
View STEAP2 Products |
| Related Target B | CD3E T-cell engager (Bispecific) partner pathway for STEAP1×CD3 constructs. |
View CD3E Products |
| Related Target C | PSMA (FOLH1) Established prostate membrane antigen benchmark and combination strategy reference (e.g., STEAP1×PSMA bispecifics). |
View FOLH1 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native 6-TM Conformation | Lentivirus-mediated stable cell lines expressing full-length STEAP1; maintains six-TM topology for flow cytometry and internalization assays. |
| Cross-species Cyno/Mouse Evaluation | Human/Cyno/Mouse ortholog proteins available; Sequence Verified, >95% purity for consistent bridging studies. |
| Subfamily Selectivity (vs STEAP2) | STEAP2 homolog panel protein; Sequence Verified, >95% purity, mass-spectrometry confirmed for counter-screening. |
| Internalization Efficiency (ADC) | Lentivirus stable cell lines preserve native conformation for FACS-based internalization quantification. |
| Specificity Controls & False Positives | Clinical Benchmark Antibodies (biosimilars) and validated siRNA set included for knockdown specificity checks. |
Live STEAP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for STEAP1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Bispecific T-Cell Engagers (TCEs) and next-generation Antibody-Drug Conjugates (ADCs). Because STEAP1 is a six-transmembrane epithelial antigen with highly restricted expression in prostate cancer and Ewing sarcoma, it offers an exceptional therapeutic window. As first-generation therapies (e.g., AMG 509 by Amgen, AZD7495 by AstraZeneca) advance through early clinical stages, the next wave of R&D is targeting optimized bispecific formats to balance efficacy with cytokine release syndrome (CRS) mitigation, alongside novel payload ADCs to overcome treatment-resistant advanced solid tumors. Combination strategies with androgen receptor axis inhibitors and PSMA-directed agents are also being actively explored.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific T-Cell Engager | Amgen, Johnson & Johnson | mCRPC, Solid Tumors | Binding & Cytotoxicity Assay (Need Lentivirus-stable STEAP1+ cell lines for target cells; species-matched antigens for toxicity bridging) |
| Antibody-Drug Conjugate (ADC) | Genentech/Roche, AstraZeneca | mCRPC, Solid Tumors | Internalization Assay (Need stable cell expression preserving 6-TM topology for FACS-based quantification) |
| CAR-T Cell Therapy | Various Biotechs, Bristol Myers Squibb | mCRPC, Ewing Sarcoma | Activation Assay (Need high-purity control antigens and lentivirus-transduced target cells for scFv validation) |
| Radioligand Therapy | Emerging Innovators | Refractory PCa | Selectivity Assay (Need off-target family member validation, e.g., STEAP2 protein) |